Company ProfilePremium

Micro-X Limited

Company Profile Analysis

Ticker: MX1.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Micro-X Limited - Company showcase

Year Founded & Workforce

2011

Micro-X Limited logo

Micro-X Limited Employee Contacts

6 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Micro-X Limited Overview

Micro-X is an Adelaide-based developer and vertically integrated manufacturer of X-ray imaging systems. Its systems are built on a proprietary cold-cathode carbon-nanotube (CNT) emitter platform branded "NEX" (Nano Electronic X-ray) Technology. The CNT emitters are switched electronically rather than heated, so the tubes and high-voltage generators are smaller, lighter and lower-power than conventional filament designs. This enables mobile radiography (the Rover/Rover Plus), a stationary multi-source Head CT for pre-hospital stroke diagnosis, a portable Full Body CT, and miniaturised CT baggage scanners for airport self-screening checkpoints. The business is pre-profit and has a material-uncertainty going-concern emphasis. Revenue is dominated by non-dilutive engineering contracts with US government agencies (DHS, ARPA-H), the Australian Stroke Alliance and industrial partners (Varex, Billion Prima), with a smaller and lumpy product business. In August 2026 a new technologist CEO launched a "strategic reset" focused on medical CT. It was funded by A$8M of secured 12% convertible notes.


Company's own description

The FY25 directors' report describes the principal activities as the design, development, manufacture and commercialisation of imaging products for global healthcare and security markets, using the company's proprietary cold-cathode X-ray technology [AR-FY25]. The standard "About Micro-X" boilerplate (2026) adds three points [ASX-03Aug26]:

  • The company has a fully vertically integrated design and production facility in Adelaide and a technical and commercial team in Seattle.

  • Its first mobile digital radiology products are sold for healthcare, military and veterinary imaging.

  • DHS has contracted it to design a next-generation airport checkpoint, a miniature brain CT for ambulances is government-funded, and ARPA-H contracted it in November 2024 to develop a full-body CT.

Independent characterisation

Micro-X is best understood as a platform-technology engineering house that is still converting into a product company. Its economic engine has three parts.

  1. Funded development (largest revenue line). Government and corporate partners pay Micro-X to adapt NEX tubes and generators to their applications. Engineering contract services were A$10.463M of A$13.053M FY25 revenue (80%) [AR-FY25]. Revenue is recognised over time, on hours and inputs for fixed-price contracts and on time-and-materials for DHS.

  2. Product sales (Mobile DR). The Rover / Rover Plus mobile X-ray carts, imaging chains and spare parts are sold direct and via distributors to hospitals, militaries, NGOs (Ukraine), elite sports teams and veterinary users. Product revenue is highly lumpy: A$6.410M in FY24, A$2.590M in FY25, and A$4.405M in H1 FY26 alone, of which A$3.36M was one Malaysian MoH order [AR-FY25, HY26].

  3. Component and licensing economics (emerging). These include the A$7.5M exclusive multi-beam tube licence to Varex Imaging (FY23) and a model under which Billion Prima buys Micro-X tubes and generators for each baggage/parcel scanner it sells (from its planned 2026 launch) [AR-FY23, AR-FY25].

A fourth, non-operating support is the Australian R&D Tax Incentive (RDTI). It contributed A$6.647M (FY23), A$6.373M (FY24) and A$5.430M (FY25) of "other income" [AR-FY23, AR-FY25]. Only companies with aggregated turnover below A$20M qualify for the refundable cash offset. This creates a perverse threshold effect: management did not book RDTI in H1 FY26 because it was unsure it would stay under A$20M [HY26]. FY26 revenue ended at A$15.087M [4E-FY26], and about A$2M of net FY26 RDTI is expected in October 2026 [4C-Q4FY26].

Revenue model mix

Revenue type (AUD Mn)FY23FY24FY25
Sale of goods (product)3.7956.4102.590
Engineering contract services11.2108.81210.463
Total revenue15.00515.22213.053
Other income (mostly RDTI)7.3906.7405.591

Sources: [AR-FY23], [AR-FY25]. Subscription or recurring service revenue is not separately disclosed and appears immaterial. Licensing appears inside engineering services (Varex).

Value-chain position

Micro-X is vertically integrated from the core component (CNT emitter, X-ray tube, solid-state epoxy-encapsulated high-voltage generator delivering 160 kV DC [AR-FY23]) through to system integration (Rover carts, CT arrays, checkpoint portals) and reconstruction software and algorithms. It buys detectors (e.g., Varex Lumen glass-free detector on Rover 2026 [HY26]), millimetre-wave body scanning (Voxel Radar) and AI threat-detection collaborations (Johns Hopkins) from third parties [AR-FY25].

Customer types and end-markets

End-marketCustomer typesRepresentative customers / counterparties
Hospital & ambulatory radiologyHealth systems, GPOs, distributorsUnnamed major US provider (>700 facilities, Jul 2025 supply agreement); Malaysian MoH via IMS; Vertec Scientific (UK)
Military / humanitarianDefence forces, NGOs, governmentsAustralian Defence Force (JP2060 Ph3); Ukraine (13 charity-funded + 16 Australian-government-funded Rovers)
Sports medicineProfessional teams9 Rover Plus systems across 8 MLB teams; NHL Arizona Coyotes; first NBA team (H1 FY26)
Pre-hospital stroke (development)Ambulance services, hospitalsAustralian Stroke Alliance / Royal Melbourne Hospital
Rural / mobile CT (development)US health agenciesARPA-H
Aviation security (development)US governmentDHS Science & Technology Directorate / TSA labs
Cargo / parcel security (partner)OEMBillion Prima (Malaysia)
OEM components / licensingX-ray tube OEMsVarex Imaging

Strategy

Strategic themes over time

FY23 "Strategy Refresh" (Aug 2023): Leverage the technology for commercial benefit; target larger, less competitive markets; de-risk and cut costs; use partnerships to create value; create recurring revenue [AR-FY23].

Jan 2025 "Strategy reset.": Focus on medical imaging (Rover Plus, Head CT, Full Body CT); discontinue Argus; seek partners to monetise security assets (Checkpoints, baggage scanner); pursue funded development only [AR-FY25].

Aug 2026 "Strategic reset" (FY27) [ASX-03Aug26]: 1. Medical CT priority. Development refocused on medical CT, which the company calls its largest future market. Imaging trials run in Melbourne, with Adelaide to follow.

  1. Financial rigour. New CFO; stronger project cost control, capital allocation and board reporting.

  2. Restructured Rover sales. A 10-week review by Seattle consultancy Altus Alliance led to CRM, pipeline, tender strategy and scalable resourcing changes ahead of the Rover 2026 launch.

  3. Cost savings. >A$3M annualised (about A$2M employment, A$1M overhead), about 15% of the FY26 core cost base; substantially implemented, with the balance in H1 FY27.

  4. Funding runway. Stated to extend through FY27, supported by A$8.1M of contracted development receipts from FY27 onward (milestone-dependent).

Initiatives register (last 24 months)

InitiativeDateTypeDetail
ARPA-H Full Body CTNov/Dec 2024 → ongoingNew business / funded R&DUp to A$25M; CDR complete Jun 2026
Argus discontinuationJan 2025Portfolio pruning~A$0.7M p.a. savings; A$1.871M impairment
Billion Prima partnershipFeb 2025; expanded Dec 2025Partnership + equityA$5.6M development deal; A$5.4M total equity
Security monetisation process2025–26Strategic reviewEngagement with multiple parties; no deal announced
US health-system supply agreementJul 2025CommercialFramework with >700-facility provider; no initial orders on signing
IGP ambulance Head CT grantSep 2025GrantA$4.4M
Rover 2026Nov 2025Product refreshVarex Lumen detector
Lung CT researchJun 2026Platform extensionA$1.3M to Micro-X
Sustainability strategyFY25 → reporting from 1 Jul 2026ESGVoluntary AASB S1/S2-referenced disclosures
Convertible-note-funded resetAug 2026Capital / transformationA$8M notes; use of proceeds: ~45% Head CT, ~20% Rover launch, ~20% opex, ~10% working capital, ~5% costs

Medium-term targets / guidance

Micro-X does not publish revenue or earnings guidance. Stated objectives are:

  • Head CT regulatory submission by the end of 2026 [HY26].

  • Funding runway through FY27 [ASX-03Aug26].

  • Improving net operating cash flow in coming quarters, with about A$2M of net FY26 RDTI expected in October 2026 [4C-Q4FY26].

  • Achieving "cashflow stability" via CT products [ASX-03Aug26].

Products & Services

Core platform: NEX (Nano Electronic X-ray) Technology

Description: Patented cold-cathode emitter containing millions of carbon nanotubes that emit electrons by field emission into an anode. There is no heated filament, which allows instant electronic on/off switching and a controllable focal spot [AR-FY23].

Components: CNT X-ray tubes (including the "mini tube" for CT arrays) and an in-house solid-state high-voltage generator. The generator is epoxy-encapsulated, delivers 160,000 V DC and was commercialised in 2023 [AR-FY23].

Commercial history: First NEX tubes commercially produced in 2019 [AR-FY23].

Monetisation routes: Embedded in own products, licensed (Varex multi-beam), and supplied as components (Billion Prima).

Medical imaging: commercial

ProductDescription & key capabilitiesTarget customerLaunch / latest versionPricing / channelStatus
Rover PlusUltra-mobile digital radiography cart on NEX tube and in-house generator; lightweight, manoeuvrable, ruggedised; FDA 510(k) (with Varex flat-panel detector) and ARTG listedHospitals, urgent care, military field hospitals, NGOs, sports teams, vetsLaunched Sep 2022 [AR-FY23]Direct and distributors (MXR, Medlink historically; Vertec UK; IMS Malaysia). Unit pricing not disclosed. Framework pricing with major US provider.Commercial; restructured sales function from FY27
Rover 2026 (updated Rover)Glass-free Varex Lumen detector, integrated detector charging, larger screen, streamlined chassisSameUnveiled at RSNA Nov 2025; "available shortly" per [HY26]; commercial launch funded by convertible notes [ASX-03Aug26]—Launching FY27
Rover (original)Ruggedised successor to Nano; proven in Ukraine front-line surgical unitsMilitary/humanitarianc. 2019DirectLegacy
Nano / DRX-Revolution NanoFirst-generation mobile DR; OEM version sold via CarestreamHospitalsc. 2017OEMWound down (nil FY25 revenue)
Imaging chainsNEX tube + generator + control sub-system sold as a moduleOEMs, partnersFirst reported FY25 (A$0.481M)—Active
Spare parts & serviceReplacement parts, servicingInstalled baseOngoing—A$0.3M p.a.

Medical imaging: development

ProductDescriptionFundingStage (latest)Next milestones
Head CT ("Stroke Scanner", formerly Brain CT)Stationary cone-beam CT using an array of purpose-built NEX mini tubes (21 tubes per FY23 design) in a curved arc; designed to fit road and air ambulances to diagnose stroke type within the "golden hour"A$8.0M ASA contract (MRFF-funded "Stroke Golden Hour"); A$4.4M Industry Growth Program grant for the ambulance configurationFirst full 3D phantom images FY25. First test bench at Royal Melbourne Hospital in Feb 2026. Human imaging pilot from 3 Jun 2026; multi-centre pilot recruiting 100+ patients (~108) with blind comparison to conventional CT; first CNT cone-beam CT human brain images reported.Second and third test benches (Adelaide to follow); regulatory submission targeted by end-2026 [HY26]; ambulance trial
Full Body CTPortable, lightweight full-body CT for rural and remote US patients, leveraging Head CT mini tubes and algorithmsARPA-H contract up to A$25M (US$16.4M). Initial two-year A$12.5M component. Some media (Stockhead) reported "up to US$25M"; company filings state A$25M / US$16.4M.Design concept and preliminary design reviews done (A$2.7M, H1 FY26); Critical Design Review (Milestone 7) Jun 2026 (A$1.6M)Build full-size engineering prototype / test bench; imaging studies toward FDA
Lung CT (research)Feasibility of a stationary NEX CT array for early lung-cancer screening; laboratory test bench only, not a clinical deviceA$1.9M Critical Technologies Challenge Program; Micro-X receives A$1.3M for hardware, support and servicesAgreement executed Jun 2026; 18-month program led by University of SydneyLab feasibility results

Security products

ProductDescriptionFunding / partnerStatus
Passenger Self-Screening CheckpointReplaces the conveyor-plus-walk-through lane with seven self-screening stations in the same footprint, scanning passenger and bag simultaneously. Integrates Micro-X CT baggage scanner, Voxel Radar mm-wave body scanning, Johns Hopkins deep-learning models and Monash Design Health Collab design.DHS S&T; total program up to US$20.9M (A$31.7M)One checkpoint portal and two baggage scanners in TSA lab evaluation; two more checkpoints manufactured; extension to 30 Sep 2026 for algorithm work
Miniaturised CT Baggage ScannerCompact modular NEX-based CT for carry-on bags; potential standalone use (stadiums, prisons, buildings)DHS S&T; Sep 2026 8-month extension (~A$1.05M) to improve imaging speed and design for manufactureFirst prototype 2024; four prototype scanners built in total; upgraded design in progress
Billion Prima baggage & parcel scannerPartner-branded X-ray scanner with NEX tubes and generatorsA$5.6M partnership (A$3.2M development milestones plus equity)Prototype delivered Sep 2025; shown at Kuala Lumpur expo Oct 2025; partner launch planned 2026; Micro-X earns per-unit component revenue
Argus X-ray CameraPortable backscatter imager for explosive-ordnance disposal; stand-off imaging transmitted to a tablet over 1,500 m; iF Design AwardPreviously Defence-supportedDiscontinued 31 Jan 2025; A$1.871M impairment in FY25
Mobile Backscatter Imager (historic)Counter-IED predecessor concept, with Thales collaboration—Superseded by Argus, then discontinued

Licensing

Varex multi-beam tubes: Exclusive global licence (A$7.5M / US$5.0M) for Varex to make multi-beam tubes using NEX. Technology transfer completed in FY25. Micro-X continues to customise its high-powered generator for Varex tubes [AR-FY23, AR-FY25].

Financial Narrative

Income statement

Sources: [AR-FY23] (FY22–23), [AR-FY25] (FY24–25), [4E-FY26]. FY22 revenue split: Mobile DR sales of A$3.8M stated in [AR-FY23]; engineering derived as the residual. FY22 growth is computed against FY21 revenue of A$3.77M (aggregator, TipRanks). Derived EBIT = pre-tax loss + finance expense. Derived EBITDA = EBIT + D&A. Both include RDTI other income. Gross profit is product-only because engineering services have no disclosed cost of sales.

Revenue CAGR FY22–FY26 (derived): 13.9%. FY23–FY26 CAGR: 0.2% (derived). Revenue has plateaued at A$13–15M for four years.

H1 FY26 bridge [HY26]: revenue A$10.107M (+155%); product A$4.405M; project A$5.702M; other income A$1.138M (vs A$3.440M; RDTI not booked); net loss A$6.617M (vs A$8.681M). Implied H2 FY26 revenue: A$4.98M (derived: 15.087 - 10.107). Implied H2 FY26 net loss: A$3.26M (derived; probably helped by catch-up RDTI recognition once the sub-A$20M turnover condition was confirmed).

Commentary.

FY23 inflection: Revenue rose 67% on the Varex technology transfer, DHS and ASA services. The loss narrowed 37%.

FY24: Flat revenue, but the mix shifted to product: A$3.0M of Ukraine and Australian military government sales lifted goods revenue to A$6.4M [AR-FY25].

FY25 regression: Rover sales collapsed 71% as the company pivoted to longer-cycle tenders. The Argus exit cost A$1.871M of impairment, and the loss widened to A$13.9M.

FY26 recovery: The Malaysian MoH order and ARPA-H milestones drove revenue +16% and loss -29%. The improvement relies on one A$3.36M order and milestone timing, not on a recurring run-rate.

Cost base: Employee costs have been stuck at A$16–17M p.a. since FY22 despite two cost programs (A$2M in 2023, A$0.7M Argus in 2025). The FY27 reset targets a further >A$3M (about 15% of the FY26 core operating cost base) [ASX-03Aug26]. This implies an FY26 core operating cost base of about A$20M (derived).

Balance sheet

Sources: [AR-FY23], [AR-FY25], [4E-FY26], [4C-Q4FY26] (FY26 cash, rounded). Note a discrepancy: [AR-FY25] reports FY25 net assets as A$7.548M on the balance sheet but A$7.458M in the going-concern note (apparent typographical transposition).

31 Dec 2025 (interim) [HY26]: total assets A$17.411M; cash A$4.896M; borrowings nil (R&D loan repaid Oct 2025); lease liabilities A$2.826M; total liabilities A$11.753M; equity A$5.658M; accumulated losses A$142.087M.

Commentary. Equity has fallen from A$34.2M (30 Jun 2021) to A$5.7M (Dec 2025). Cumulative losses exceed A$142M against A$142.8M of paid-in capital, which means essentially all capital raised since 2011 has been consumed. Debt has been limited to (i) leases on Tonsley and Seattle premises and (ii) short-term RDTI advance loans at 15–16%. The capital structure changes materially in FY27: A$8M of three-year secured convertible notes at 12% compounding monthly are secured over substantially all assets [ASX-03Aug26]. Inventory of A$4.0–4.3M is largely Rover-related and partly Argus (written down) and is a meaningful latent cash source.

Cash flow

Sources: [AR-FY23], [AR-FY25]. FY26 OCF is derived as H1 (-3.047 [HY26]) + Q3 (-2.7 [4C-Q3FY26]) + Q4 (-3.161 [4C-Q4FY26]). The H1 figure was depressed by A$3.985M because the ATO remitted the RDTI refund directly to the lender. On a normalised basis H1 FY26 OCF was +A$0.938M [HY26]. FY26 equity proceeds are the December 2025 placement headline (A$6.18M) [4E-FY26].

Commentary. Cumulative FCF burn over FY22–FY25 was about A$46.5M (derived). Equity raised over FY23–FY26 was about A$25.9M (derived). Partner and RDTI cash covered the gap. The burn has fallen from A$18M (FY22) to A$6–9M, but there is still no organic path to cash breakeven without (a) Rover volume or (b) large milestone receipts.

Ratios

All ratios are derived from [AR-FY23] and [AR-FY25]. ROIC, net debt/EBITDA and interest coverage are not meaningful because EBIT and EBITDA are negative. The cash conversion cycle is not meaningful because receivables are dominated by the RDTI receivable (A$5.39M of A$8.32M at FY25). H1 FY26 current ratio: 1.45 (derived).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment metric (AUD Mn)FY25H1 FY26

Australia: external sales

4.2124.809

Australia: other revenue

5.5911.061

Australia: profit/(loss) before tax

-15.036-7.102

United States: external sales

8.8415.298

United States: other revenue

00.077

United States: profit/(loss) before tax

1.1410.485

Group total revenue (incl. other)

18.64411.245

Group loss before tax

-13.895-6.617

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product line revenue (AUD Mn)

Product line revenue (AUD Mn)FY24FY25

Micro-X Rover / Rover Plus

5.3461.561

DRX-Revolution Nano

0.7430

Spare parts

0.3210.302

Micro-X Argus

00.246

Micro-X imaging chains

00.481

Engineering contract services

8.81210.463

Total

15.22213.053

Counterparty revenue (AUD Mn)

Counterparty revenue (AUD Mn)FY24FY25H1 FY26

US DHS (checkpoint & baggage CT)

4.24.5701.956

ARPA-H (Full Body CT)

03.1923.031

Billion Prima (baggage/parcel scanner)

01.8990.464

Australian Stroke Alliance (Head CT)

1.00.6200.251

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

8.97015.00515.22213.05315.087

Revenue growth YoY (%)

138.067.31.4-14.215.6

Sale of goods (AUD Mn)

3.83.7956.4102.590—

Engineering contract services (AUD Mn)

5.211.2108.81210.463—

Other income incl. RDTI (AUD Mn)

4.1447.3906.7405.591—

Change in inventory / materials (AUD Mn)

-3.970-3.505-5.777-2.734—

Product gross profit, derived (AUD Mn)

-0.1700.2900.633-0.144—

Product gross margin, derived (%)

-4.57.69.9-5.6—

Employee & director expenses (AUD Mn)

15.89417.01916.62317.252—

Project development expenses (AUD Mn)

4.4446.4443.7084.338—

Impairment (AUD Mn)

0001.871—

Depreciation & amortisation (AUD Mn)

1.4321.5891.5391.570—

Finance expenses (AUD Mn)

0.2960.2690.2480.561—

Operating income (EBIT), derived (AUD Mn)

-16.793-10.485-9.517-13.334—

EBITDA, derived (AUD Mn)

-15.361-8.896-7.978-11.764—

Pre-tax income (AUD Mn)

-17.089-10.754-9.765-13.895-9.876

Net income (AUD Mn)

-17.089-10.754-9.765-13.895-9.876

EPS basic (A cents)

-3.71-2.17-1.85-2.28—

EPS diluted (A cents)

-3.71-2.17-1.85-2.28—

Dividends per share (A cents)

00000

EBITDA margin, derived (%)

-171.2-59.3-52.4-90.1—

Operating margin, derived (%)

-187.2-69.9-62.5-102.2—

Net margin (%)

-190.5-71.7-64.2-106.5-65.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

31.27730.29826.89522.106—

Cash & equivalents (AUD Mn)

10.3035.2233.2283.2423.1

Trade & other receivables (AUD Mn)

3.7556.9967.2128.321—

Inventories (AUD Mn)

5.7837.3385.3794.274—

Total current assets (AUD Mn)

22.74422.43719.89817.080—

Total current liabilities (AUD Mn)

6.4798.3188.63311.308—

Working capital, derived (AUD Mn)

16.26514.11911.2655.772—

Short-term borrowings (AUD Mn)

0003.375—

Lease liabilities, current (AUD Mn)

0.6330.7260.6920.659—

Lease liabilities, non-current (AUD Mn)

4.6813.9773.2982.499—

Total debt incl. leases, derived (AUD Mn)

5.3144.7033.9906.533—

Net debt / (net cash) incl. leases, derived (AUD Mn)

-4.989-0.5200.7623.291—

Goodwill (AUD Mn)

0000—

Intangibles (AUD Mn)

0.1440.1320.1200.024—

Total liabilities (AUD Mn)

11.98813.10512.63414.558—

Total equity (AUD Mn)

19.28917.19314.2617.548—

Accumulated losses (AUD Mn)

-101.380-112.134-121.773-135.470—

Issued capital (AUD Mn)

117.529125.396131.933138.350—

NTA per share (A cents)

4.153.33—1.140.68

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-18.108-10.993-6.435-8.591-8.9

Capex incl. intangibles (AUD Mn)

1.1120.7790.3690.100—

Free cash flow, derived (AUD Mn)

-19.220-11.772-6.804-8.691—

Proceeds from share issues (AUD Mn)

07.4555.9216.3656.18

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

RDTI cash refunds (AUD Mn)

2.0793.8856.2326.414—

Receipts from customers (AUD Mn)

4.0993.8946.9902.788—

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE on average equity (%)

-63.9-59.0-62.1-127.4

ROA on closing assets (%)

-54.6-35.5-36.3-62.9

Current ratio (x)

3.512.702.301.51

Debt incl. leases / equity (x)

0.280.270.280.87

Asset turnover, revenue / closing assets (x)

0.290.500.570.59

Inventory days on product COGS, derived

532764340571

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2024FY2025

United States

9.4639.040

Asia-Pacific

4.3242.979

Europe & EMEA

1.4351.034

Total

15.22213.053

Region growth / mix (%)

Region growth / mix (%)FY2024FY2025

United States share (%)

62.269.3

Asia-Pacific share (%)

28.422.8

Europe & EMEA share (%)

9.47.9

United States YoY (%)

—-4.5

Asia-Pacific YoY (%)

—-31.1

Europe & EMEA YoY (%)

—-27.9

Entity external sales (AUD Mn)

Entity external sales (AUD Mn)FY2025H1 FY2026

Micro-X Limited (Australia, incl. UK)

4.2124.809

Micro-X Inc (US)

8.8415.298

Share Price History

DatePrice (AUD)Context

Sep 2023 (approx.)

0.105

After CEO appointment (AU Manufacturing, May 2023 reference: A$0.105, ~A$48.9M market cap)

Apr 2024

0.095

Placement and SPP price

Mid-Sep 2024

0.050

12-month low (Stockhead)

Early Dec 2024

0.097

12-month high (Stockhead)

Feb 2025

0.070

Placement / entitlement price

30 Jul 2025

0.090

US supply agreement spike

Sep 2025

0.093

IGP grant spike

Dec 2025

0.080

Placement price

23 Feb 2026

0.070—

30 Apr 2026

0.054

Q3 4C release

10 Jun 2026

0.038

ARPA-H CDR

24 Jul 2026

0.030—

28 Aug 2026

0.026

FY26 results

Early Sep 2026

0.017

Cycle low

23 Sep 2026

0.041

ASX price query

8 Oct 2026

0.054

Latest close

Return (derived, approximate)

Return (derived, approximate)Value

~1-year (Sep 2025 A$0.093 → Oct 2026 A$0.054) (%)

-42

~3-year (May 2023 A$0.105 → Oct 2026 A$0.054) (%)

-49

Valuation Multiples

MultipleMicro-XComment

EV/Sales (FY26)

~2.7x

EV ≈ market cap + leases (~A$2.8M) - cash (A$3.1M); excludes A$8M notes if settled

P/B

~7–8x

—

Price / NTA

~7.9x

NTA 0.68c per share (FY26)

Capital Instruments

InstrumentAmount (AUD Mn)RateMaturitySecurity

Convertible notes (if fully settled)

8.0

12% p.a., compounding monthly, cash or capitalised

~Oct 2029 (3 years from issue)

General security deed over substantially all assets

Lease liabilities (Dec 2025)

2.826

Implicit

Current 0.589; non-current 2.237

Leased premises

RDTI advance loans (historic)

0 at Dec 2025

15–16%

Repaid from RDTI refunds

RDTI receivable

Share Count (M) and Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Shares on issue at period end (M)

—514.4581.6667.2—

Equity raised (AUD Mn)

07.4555.9216.3656.18

Analyst Conclusions

Management guidance and expectations

  • No numeric revenue or earnings guidance.

  • Stated objectives: Head CT regulatory submission by end-2026; funding runway through FY27; improving operating cash flow; about A$2M of FY26 RDTI in October 2026.

  • Contracted development receipts: A$8.1M from FY27 onward (milestone-dependent).

  • More than A$3M of annualised cost savings [HY26; 4C-Q4FY26; ASX-03Aug26].

  • Consensus (2 analysts): continued losses (FY27 EPS about -A$0.01); target A$0.15.

Bull case

  1. Head CT is a category-creating asset. Human imaging is underway at RMH with 100+ patients targeted, and it is funded by MRFF (A$8M) plus IGP (A$4.4M). Success would make Micro-X the first company with an ambulance-deployable stationary CT for stroke, in a market the company sizes at US$5B.

  2. Government partners keep paying. DHS (up to A$31.7M), ARPA-H (up to A$25M) and ASA fund the platform's development. Every disclosed ARPA-H milestone has been hit. CEO Gonzales personally originated these relationships.

  3. Operating leverage is visible. H1 FY26 showed what a single tender (A$3.3M) does to revenue (+155%) and losses (-24%). Rover 2026, the 700-facility US framework, Billion Prima component sales and >A$3M of cuts could compound.

Bear case

  1. Balance-sheet fragility. Cash was A$3.1M at June 2026 against an operating burn of about A$9M p.a. Going-concern emphasis has appeared in every recent set of accounts. Funding now relies on 12% secured debt that ranks ahead of equity.

  2. Commercial execution has repeatedly disappointed. Argus failed. Rover revenue fell 71% in FY25. FY26 revenue (A$15.1M) missed consensus (A$26.9M) by 44%. The Chair has conceded execution shortfalls.

  3. Dilution and structural drag. About 100M+ shares on note conversion, a large rights pool, and the RDTI cliff at A$20M revenue. Success itself could cut A$5–6M p.a. of tax-refund support just as scaling costs rise.

Catalysts and monitorables (next 12 months)

  • Settlement confirmation of the A$8M notes and director tranche (due by 2 Oct 2026).

  • Receipt of about A$2M of FY26 RDTI (Oct 2026); Q1 FY27 Appendix 4C (late Oct 2026).

  • AGM (Nov 2026 expected): remuneration vote, board renewal, any Billion Prima nominee.

  • Head CT pilot data readout and regulatory submission (target end-2026).

  • ARPA-H full-size prototype build milestones and payments.

  • Rover 2026 commercial availability; first orders under the US 700-facility framework.

  • Billion Prima scanner commercial launch and first component orders.

  • Any security-asset monetisation transaction.

  • DHS follow-on funding beyond the current extensions (federal FY27 budget).

  • H1 FY27 results (Feb 2027): first read on cost savings.

Analyst verdict

Micro-X is a genuinely differentiated technology company trapped in a small-cap funding loop. The technical record is credible. A cold-cathode CNT tube and generator stack has been industrialised in Adelaide. The world's largest tube OEM licensed it and invested in it. Two US federal agencies and an Australian clinical consortium have funded it into stationary-array CT systems that would be hard to build with conventional filament tubes. The Head CT human pilot that began in June 2026 is the most important de-risking event in the company's history. The Full Body CT program has passed every disclosed design gate.

The commercial record is weak. Over five years revenue has plateaued at about A$13–15M. Product gross margins have hovered near zero. One flagship product was abandoned. Losses have consumed essentially all A$142M of contributed capital. The August 2026 reset is a credible diagnosis: it narrows focus to CT, puts the originator of the government programs in charge, cuts costs and professionalises Rover selling. But its funding instrument, A$8M of 12% secured converts, tells investors that equity markets were effectively closed at prevailing prices. The capital structure is now senior-debt-heavy relative to the size of the business.

At about A$40M market cap and about 2.7x FY26 EV/sales, the equity is a long-dated, binary option on Head CT clinical and regulatory success and on Micro-X becoming a component supplier to larger partners. Non-dilutive government cash partly underwrites that option, but serial dilution and going-concern risk weigh on it. We characterise the stock as speculative / high-risk. Monitor the Head CT pilot data, Q1–Q2 FY27 cash burn against the >A$3M savings claim, and whether Rover 2026 converts the US framework into recurring orders. Absent at least two of these by mid-2027, a further recapitalisation on dilutive terms is the base case.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / educationFY25 total remuneration (AUD)

Dr Brian Gonzales

Chief Executive Officer (from 3 Aug 2026)

Joined 2017 (Lead Scientist); CSO & CEO of Micro-X Inc from 1 May 2023

21+ years in cold-cathode X-ray. PhD from University of North Carolina / NC State (CT algorithms with CNT X-ray). Secured the DHS program (US$3.5M grown to >US$16M awarded) and the US$16M ARPA-H program. Manages the Varex and Billion Prima partnerships (US$7M contract revenue 2023–26).

529,046 (as CSO / CEO Americas)

Peter Dickman

Chief Financial Officer

Since end-March 2026

Prior roles not disclosed in sources reviewed

Not yet disclosed

Anthony Skeats

—

COO since 1 May 2023

MEng (Hons)

535,063

Richard Willson

Company Secretary

Since 30 May 2025

25+ years as Company Secretary / NED / CFO across ASX tech and resources companies

n/a (KMP not disclosed)

Kingsley Hall

Former CEO (1 May 2023 – 3 Aug 2026); adviser to 3 Nov 2026

CFO from Feb 2020

BEc (Flinders); 25+ years in finance and operations

569,446

Board of Directors

DirectorRoleAppointedIndependenceBackgroundFY25 fees (AUD)Shareholding

Patrick O'Brien

Non-Executive Chair (Chair since 15 Jan 2025); chairs Audit & Risk and People & Remuneration per FY25 report

Aug 2015

Independent NED (substantial shareholder)

Ex-Macquarie Senior MD (corporate finance, private equity), McKinsey, Minter Ellison; Chair GCQ Funds Management, CE Bartlett

54,905

12,787,591 indirect shares + 526,316 options (Apr 2026); bought 2.5M at A$0.08 (Apr 2026)

James McDowell

NED

Pre-FY22

Independent

Ex-CEO BAE Systems Australia; ex-Deputy Secretary Naval Shipbuilding (Defence); ex-CE SA Dept Premier & Cabinet; NED Metal Powder Works (ASX:MPW)

54,905

1,594,466 shares (FY25)

Ilona Meyer

NED; Chair of Audit & Risk Committee

7 Mar 2022

Independent

General Counsel & CoSec, Nuix; ex-Boehringer Ingelheim, ResMed, Medtronic, 3M

57,497

589,043 shares (FY25)

Andrew Hartmann

NED (Varex nominee, unpaid)

15 Dec 2022

Not independent (major partner nominee)

SVP & GM Imaging Solutions, Varex; ex-Philips, Carestream, Siemens

0

357,143 shares (FY25)

Billion Prima nominee

NED (contractual right on tranche-2 settlement)

Expected by Mar 2026

Not independent

———

Board & Management Changes

DateChangeContext

1 May 2023

Rowland → NED; Hall → CEO

Shift from founder-technologist to commercial leadership

12 Nov 2024

Gosling resigns

Board reduction

15 Jan 2025

Knox resigns; O'Brien Chair

Coincides with strategy reset

30 May 2025

Willson replaces Hall as CoSec

Governance separation

Late Mar 2026

Dickman appointed CFO

Strengthen financial controls

3 Aug 2026

Gonzales replaces Hall as CEO

The Chair said the company had not yet delivered commercial execution matching its technology; reset prioritises medical CT

Major Shareholders

HolderStake / positionSource

Thorney Investment Group (Thorney Technologies Ltd et al.)

Substantial holder (≥5%); notice of dilution 2 Jan 2026. TIGA Trading (Thorney) is underwriter of A$2M of the convertible notes.

Form 604, 2 Jan 2026; [ASX-03Aug26]

Billion Prima Sdn Bhd

About 8.6% after Dec 2025 placement (37.5M new shares at A$0.08 plus 26.7M at A$0.09 in 2025)

[HY26]

Bindella Capital

Existing shareholder; committed A$5M of notes; would become substantial on conversion (62.5M shares at A$0.08)

[ASX-03Aug26]

HSBC-custodied holder

Ceased to be substantial holder on 1 Sep 2026 after on-market sales

ASX Form 605, 3 Sep 2026

Patrick O'Brien (Chair)

About 12.8M shares

MarketIndex

Directors & KMP aggregate

15.56M shares at 30 Jun 2025 (about 2.3%) plus ~A$0.8M of notes committed (directors' portion subject to shareholder approval)

[AR-FY25]; [ASX-03Aug26]

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs. Micro-X

Mobile DR

GE HealthCare (AMX Navigate / Optima mobile)

Incumbent; scale, service network, GPO contracts

Mobile DR

Siemens Healthineers (Mobilett series)

Incumbent premium

Mobile DR

Philips (MobileDiagnost)

Incumbent

Mobile DR

Carestream Health (DRX-Revolution; former OEM partner)

Incumbent; ex-partner

Mobile DR

Fujifilm (FDR Go / FDR nano)

Direct lightweight-cart competitor

Mobile DR

Canon Medical, Shimadzu, Agfa (DR 100s), Konica Minolta

Broad competition

Portable / point-of-care CT

Samsung NeuroLogica (OmniTom, CereTom)

Established portable head CT; rotating gantry

Portable / point-of-care CT

Siemens Healthineers (SOMATOM On.site head CT)

Bedside head CT

Point-of-care brain imaging (alternative modality)

Hyperfine (Swoop portable MRI)

Substitute for bedside neuro-imaging

CNT / cold-cathode X-ray

Nanox (Nanox.ARC multi-source tomosynthesis)

Closest technology analogue

CNT / cold-cathode X-ray

XinRay / Xintek (CNT tube pioneers)

Technology competitor

Aviation CT screening

Smiths Detection, Rapiscan (OSI Systems), Leidos, Analogic

Incumbent checkpoint CT vendors with TSA certifications

Peer Comparison FY2025

CompanyLatest FY revenueGrowthMargin profileR&D intensity

Micro-X (FY26)

A$15.1M

+16%

Net margin -65%

~95% of revenue (eligible R&D, derived from FY25)

GE HealthCare (FY2024)

~US$19.7B

~flat

Profitable (low-to-mid-teens adjusted EBIT)

~5–6%

Siemens Healthineers (FY2024)

~€22.4B

~mid-single digit

Profitable

~8–9%

Nanox (FY2024)

~US$11M

Growth from small base

Heavily loss-making

Very high

Hyperfine (FY2024)

~US$12.9M

Modest

Loss-making

High

OSI Systems (FY2024, Jun YE)

~US$1.54B

Double-digit

Profitable

~4–5%

Recent Developments

--

Company Snapshot

$9.7M

Revenue

2011

Founded

Tonsley Innovation Precinct, Australia

Headquarters

SWOT Analysis

Strengths

  • Third-party technology validation. Varex, the world's largest X-ray component maker, paid A$7.5M for an exclusive multi-beam licence and invested A$7.5M of equity [AR-FY23].
  • Non-dilutive funding engine. Engineering services were A$10.463M in FY25 (80% of revenue) [AR-FY25].
  • DHS program depth. The checkpoint program is worth up to US$20.9M (A$31.7M); DHS has extended it repeatedly (Feb 2025, May 2026, Sep 2026) [HY26; ASX releases].
  • ARPA-H milestone delivery. Every disclosed milestone was achieved on schedule through the Critical Design Review (Jun 2026, A$1.6M) [ASX 10 Jun 2026].
  • Vertical integration and certification. In-house tube and generator production at Tonsley; ISO 13485 / ISO 9001; FDA 510(k) and ARTG for Rover Plus [AR-FY23, AR-FY25].
  • Clinical progress on Head CT. Human imaging pilot underway at RMH from June 2026, with 100+ patient recruitment targeted [ASX 3 Jun 2026; 4C-Q4FY26].
  • Proven ability to deliver large orders. The A$3.3M Malaysian MoH order was manufactured and delivered within about two months [HY26].

Weaknesses

  • Chronic losses. Accumulated losses of A$142.1M by Dec 2025 [HY26]; net losses every year (FY22–FY26).
  • Going-concern material uncertainty. Flagged by BDO in FY23, FY25, HY25, HY26 and FY26 [AR-FY23, AR-FY25, HY26, 4E-FY26].
  • Weak product economics. Product gross margin was -5.6% in FY25 (derived: A$2.590M sales vs A$2.734M inventory cost) [AR-FY25].
  • Lumpy Rover demand. Rover revenue fell 71% in FY25 to A$1.561M [AR-FY25]. The US framework deal came with no initial orders.
  • Customer concentration. DHS + ARPA-H = 75% of FY25 engineering revenue [AR-FY25].
  • Execution track record. Argus had delays (FY23), then was discontinued (Jan 2025) with A$1.871M of write-offs. The Chair said in Aug 2026 that the company had not achieved the commercial execution its technology warrants [ASX-03Aug26].

Opportunities

  • Head CT regulatory submission targeted by end-2026 [HY26], plus A$4.4M IGP funding for an ambulance trial.
  • Full Body CT prototype under the ARPA-H contract (up to A$25M) [AR-FY25].
  • Billion Prima scanner launch (2026). Creates per-unit tube and generator sales [HY26].
  • Rover 2026 launch with a restructured sales process (Altus Alliance review) and the 700-facility US framework [ASX-03Aug26].
  • Security asset monetisation. The baggage scanner could also be sold standalone, per the CEO in Sep 2026 (Small Caps).
  • Lung CT optionality via the University of Sydney program (A$1.3M) [ASX 16 Jun 2026].

Threats

  • Funding and dilution. A$8M of notes converting at A$0.08 would issue 100M+ shares, plus shares for capitalised interest [ASX-03Aug26].
  • RDTI cliff. Revenue above A$20M would remove the refundable RDTI, worth A$5–6.6M p.a. in FY23–FY25 [HY26].
  • US federal budget and policy risk. DHS shutdown disruption was referenced in May 2026; ARPA-H funding is discretionary [ASX 19 May 2026; AR-FY25 risk factors].
  • Incumbent competition from GE, Siemens, Philips, Fujifilm in mobile DR; Samsung NeuroLogica and Siemens in portable CT.
  • FX. Large USD-denominated costs and revenues [AR-FY25].
  • Secured creditors. The notes are secured over substantially all assets, which subordinates equity in any distress scenario [ASX-03Aug26].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Shareholders approve A$0.2M director participation in Feb 2025 placementInsider alignment
7 May 2025Director placement shares issued (2.857M at A$0.07)Completes ~A$6.4M raise
30 May 2025Richard Willson appointed Company SecretaryGovernance
Jul 2025Supply agreement with major US provider (>700 facilities)First major US health-system framework; no initial orders
30 Jul 2025Shares jump up to ~45% intraday to A$0.09 (8-month high)Market validation of Rover pivot
28 Aug 2025FY25 results: revenue A$13.053M, loss A$13.895M, going-concern uncertaintyWeak year; Argus impairment
Sep 2025A$4.4M IGP grant for ambulance Head CT; shares rise up to 17.7% to A$0.093Non-dilutive funding
Sep 2025First Billion Prima prototype delivered; baggage scanner debut at FTE GlobalSecurity partnership progress
Oct 2025A$3.3M Rover order from IMS for Malaysian MoH; delivered by mid-DecemberLargest sale in company history
Oct 2025FY25 R&D loan (A$3.99M + A$0.27M interest) repaid from RDTI refundDebt-free (ex-leases)
Nov 2025Rover 2026 unveiled at RSNA; ARPA-H showcaseProduct refresh
H1 FY26First NBA team Rover saleSports-medicine expansion
18 Dec 2025A$6.18M placement at A$0.08; Billion Prima to 8.6%Funding; strategic alignment
13 Jan 202626.9M employee rights issuedDilution / retention
Feb 2026First Head CT test bench installed at RMHClinical readiness
23 Feb 2026Response to publication of a A$1.5M CTCP grant naming Micro-X as partner (contract not yet executed)Disclosure-management event
27 Feb 2026H1 FY26 results: revenue A$10.107M (+155%), loss A$6.617M; RDTI not booked because of the A$20M thresholdStrongest half on record
Late Mar 2026Peter Dickman appointed CFOFinance leadership
24 Mar 2026General meeting resultsApprovals (incl. Chair placement participation)
24 Apr 2026Chair subscribes 2.5M shares at A$0.08 (A$200k)Insider buying
30 Apr 2026Q3 FY26 4C: cash A$3.5M; operating outflow A$2.7M; ~A$5M RDTI anticipatedLiquidity tightening
19 May 2026A$1.3M DHS checkpoint extension to 30 Sep 2026 (DHS emerging from shutdown)Program continuity
1 Jun 2026Change in substantial holdingRegister churn
3 Jun 2026Human imaging study commences with Head CTKey clinical catalyst
10 Jun 2026ARPA-H CDR complete; A$1.6M milestoneFull Body CT moves to prototype build
16 Jun 2026A$1.3M lung CT research with University of SydneyPlatform optionality
25 Jun 2026Investor presentation; securities quoted—
31 Jul 2026Q4 FY26 4C: cash A$3.1M; A$1.5M Head CT milestones received; Malaysian MoH visitRunway pressure
3 Aug 2026Gonzales CEO; strategic reset; A$8M secured convertible notes; >A$3M cost cutsPivotal restructuring
Jul–Aug 2026Shares trade around A$0.026–0.030Multi-year lows
28 Aug 2026FY26 results: revenue A$15.087M (+16%), loss A$9.876M (-29%); going-concern emphasisImprovement but still loss-making
1–3 Sep 2026HSBC-custodied holder ceases to be substantial after on-market sellingOverhang cleared
Early Sep 2026Investor Open Day at Tonsley; shares around A$0.017–0.019 (low)Investor engagement
23 Sep 2026ASX price query after ~150% weekly rise; company states no undisclosed informationVolatility
28 Sep 2026DHS 8-month miniaturised CT baggage scanner extension (~A$1.05M); results of general meetingSecurity program continuity
8 Oct 2026Shares close at A$0.054Recovery from lows

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 9 Mn in FY2022 to AUD 15.1 Mn in FY2026.
Micro-X Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue91515.213.115.1
Product gross profit-0.20.30.6-0.1—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Micro-X FY2025 Annual Report / Appendix 4E (ASX, 28 Aug 2025): announcements.asx.com.au/asxpdf/20250828/pdf/06ngr5q39fjsml.pdf
  2. Micro-X FY2023 Annual Report / Appendix 4E (ASX, 30 Aug 2023): announcements.asx.com.au/asxpdf/20230830/pdf/05t7ykdmbqxwm0.pdf
  3. Micro-X FY2022 Appendix 4E (ASX, 30 Aug 2022): announcements.asx.com.au/asxpdf/20220830/pdf/45dggpnxg5zxw2.pdf
  4. Micro-X HY2026 Appendix 4D (ASX, 27 Feb 2026): announcements.asx.com.au/asxpdf/20260227/pdf/06wvv0c8dp5kvj.pdf
  5. Micro-X HY2025 Appendix 4D (ASX, 28 Feb 2025): announcements.asx.com.au/asxpdf/20250228/pdf/06g3p9yq9sdqwv.pdf
  6. Micro-X CEO appointment, strategic reset and convertible notes (ASX, 3 Aug 2026): announcements.asx.com.au/asxpdf/20260803/pdf/072cdg869w6cdt.pdf
  7. Micro-X Q4 FY26 Appendix 4C (ASX, 31 Jul 2026): announcements.asx.com.au/asxpdf/20260731/pdf/0729pcdyz6ds56.pdf
  8. Micro-X lung CT research (ASX, 16 Jun 2026): announcements.asx.com.au/asxpdf/20260616/pdf/070nzqpl2zfy71.pdf
  9. Micro-X DHS A$1.3M extension (ASX, 19 May 2026), via Webull bulletin mirror
  10. Micro-X $6.18M placement (ASX, 18 Dec 2025): announcements.asx.com.au/asxpdf/20251218/pdf/06th625cj2qs46.pdf
  11. Micro-X DHS A$21M extension (ASX, 24 Jul 2023): announcements.asx.com.au/asxpdf/20230724/pdf/05rwrw5zljll6l.pdf
  12. Kalkine Media, FY2026 preliminary results summary (28 Aug 2026), secondary
  13. Small Caps, DHS baggage scanner extension (28 Sep 2026), secondary
  14. InDaily SA, ASX price query coverage (28 Sep 2026), secondary
  15. InvestSMART announcement and price records (accessed Oct 2026), secondary
  16. Thorney Technologies Form 604 (2 Jan 2026): HSBC Form 605 (3 Sep 2026)
  17. Reuters briefs via Stockopedia (30 Jul 2025: Sep 2025), secondary
  18. Stockhead (Dr Boreham's Crucible, 2025): AU Manufacturing (2023) · The Lead SA · Security World Market, secondary
  19. Stockopedia and Simply Wall St consensus pages (accessed Oct 2026), aggregators
  20. Marketindex director profile (Patrick O'Brien), aggregator

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.